Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

NCT04789915 is registered in ClinicalTrials.gov with Bjorn H. Ebdrup as lead sponsor.

NCT NCT04789915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04789915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Lead sponsor
Bjorn H. Ebdrup
Phase
Phase 1
Overall status
Recruiting
Start date
May 26, 2021
Completion date
December 31, 2026
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

negative symptoms with primary psychotic disorder, psychosis